Trial Profile
A Double-blind, Randomized, Multicentre Trial to Compare the Anti-tumour Effects and Tolerability of a 500 mg Dose of Faslodex (Fulvestrant) Plus Arimidex (Anastrozole) With a 500 mg Dose of Faslodex(Fulvestrant) Alone and With Arimidex(Anastrozole) Alone, in Postmenopausal Women Prior to Surgery for Primary Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Fulvestrant (Primary)
- Indications Breast cancer; Early breast cancer; Menopause
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors AstraZeneca
- 27 Mar 2010 Results presented at the 7th European Breast Cancer Conference.
- 13 Dec 2009 Results presented at the 32nd Annual San Antonio Breast Cancer Symposium
- 12 May 2009 Actual end date (October 2008) added as reported by ClinicalTrials.gov.